AWM Investment Company Inc. Invests $996,000 in Nkarta, Inc. (NASDAQ:NKTX)

AWM Investment Company Inc. bought a new position in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 400,000 shares of the company's stock, valued at approximately $996,000. AWM Investment Company Inc. owned approximately 0.57% of Nkarta as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the business. Invesco Ltd. acquired a new position in shares of Nkarta in the 4th quarter worth $30,000. Sequoia Financial Advisors LLC acquired a new position in shares of Nkarta in the 4th quarter valued at $31,000. China Universal Asset Management Co. Ltd. purchased a new position in Nkarta in the 4th quarter worth about $37,000. ProShare Advisors LLC purchased a new position in Nkarta in the 4th quarter worth about $45,000. Finally, Catalina Capital Group LLC raised its holdings in Nkarta by 57.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,818 shares of the company's stock worth $47,000 after buying an additional 6,867 shares during the period. Institutional investors and hedge funds own 80.54% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on NKTX. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Nkarta in a research report on Thursday, March 27th. Needham & Company LLC reduced their price target on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Thursday, May 15th. William Blair restated a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. Finally, Stifel Nicolaus lowered their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 27th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $14.67.

Nkarta Stock Performance

Shares of NASDAQ:NKTX traded down $0.02 during midday trading on Monday, hitting $1.75. The company's stock had a trading volume of 254,607 shares, compared to its average volume of 1,067,120. The stock's 50 day simple moving average is $1.80 and its 200 day simple moving average is $2.14. The stock has a market capitalization of $124.18 million, a price-to-earnings ratio of -0.93 and a beta of 0.81. Nkarta, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $8.23.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.01. As a group, analysts anticipate that Nkarta, Inc. will post -1.7 EPS for the current year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.